Neurocrine Biosciences, Inc. to acquire Soleno Therapeutics, Inc.

Neurocrine Biosciences, Inc. has agreed to acquire Soleno Therapeutics, Inc. in a going private transaction valued at an undisclosed amount. The deal, announced on 6 April 2026, was executed entirely through cash consideration. Both parties are based in the United States and operate within the healthcare sector. The transaction was completed on 18 May 2026, marking the end of the public listing for the target company.

This acquisition represents a significant consolidation within the US healthcare landscape, bringing the private equity-backed entity under the control of the established biopharmaceutical buyer. The structure allows the target to transition from a public to a private status without the immediate pressure of public market reporting requirements. The completion of the deal confirms that all necessary regulatory and shareholder approvals were secured in a timely manner. The transaction is now fully concluded with no further regulatory hurdles remaining.